Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.70 - $26.36
Previous CloseN/A
Volume58.73K
Average Volume (3M)419.45K
Market Cap
$698.14M
Enterprise Value$392.14M
Total Cash (Recent Filing)$471.39M
Total Debt (Recent Filing)$10.84M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
May 07, 2025EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding53,826,980
10 Day Avg. Volume465,597
30 Day Avg. Volume419,453
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.17
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.90
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$54.57Price Target Upside320.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Prothena News
PremiumCompany Announcements
Prothena Reports 2024 Financial Results and 2025 OutlookPremiumCompany Announcements
Prothena’s Balanced Earnings Call Highlights Growth and Challenges
---
Bulls Say, Bears Say
Bulls Say
Efficacy Of BirtamimabBirtamimab might lead to a 50% reduction in mortality in the Mayo Stage four patients.
Financial HealthProthena ended 2024 with over $470MM in cash and expects to end 2025 with approximately $300MM.
Market OpportunityAL amyloidosis could represent an attractive opportunity given the high unmet need.
Bears Say
Clinical ValidationSignificant clinical validation is still needed to better understand the efficacy and safety of PRX012.
Diagnosis ChallengesAmyloidosis remains a difficult to diagnose disease given that no single imaging, blood, or urine test is diagnostic for this disorder and that the presenting symptoms often mimic those of more common disorders.
PADOVA Study ResultsThe Phase 2b PADOVA study narrowly missed the statistical significance in the primary endpoint of time to confirmed motor progression.
---
Ownership Overview
13.43% Insiders
31.32% Mutual Funds
38.51% Other Institutional Investors
7.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $11.70 and its highest was $26.36 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $698.14M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Feb 20, 2025. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$1.023 by -$0.057.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.97.
How many shares outstanding does Prothena have?
Prothena has 53,826,980 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$1.08 in its last earnings report, missing expectations of -$1.023. Following the earnings report the stock price went up 2.033%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
---
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.57 (320.74% Upside)
$54.57 (320.74% Upside)
Hedge Fund Trend
Decreased
By 35.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.31%
12-Months-Change
Fundamentals
Return on Equity
-23.34%
Trailing 12-Months
Asset Growth
-21.44%
Trailing 12-Months
Company Description
Prothena
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
---
PRTA Company Deck
---
PRTA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced outlook for Prothena. While there are significant opportunities for growth through its robust portfolio and strategic partnerships, challenges remain, particularly with the dependency on future clinical trial successes and the narrow miss in prasinezumab's statistical significance.Read More>---
PRTA Stock 12 Month Forecast
Average Price Target
$54.57
▲(320.74% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alnylam Pharma
―
Biogen
―
Ionis Pharmaceuticals
―
SAGE Therapeutics
―
Best Analysts Covering PRTA
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
-3.06%
reiterated a buy rating 3 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -3.06% per trade.
---